# Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab

> **NCT05184179** · — · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 5450 (actual)

## Conditions studied

- Hypertension
- Dyslipidemia

## Interventions

- **DRUG:** Olmesartan Medoxomil

## Key facts

- **NCT ID:** NCT05184179
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-01
- **Primary completion:** 2022-08-16
- **Final completion:** 2022-08-16
- **Target enrollment:** 5450 (ACTUAL)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05184179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05184179, "Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05184179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*